Biochemical strategies for opioid-sparing pain management in the operating room
Biochemistry and Biophysics Reports,
Journal Year:
2025,
Volume and Issue:
41, P. 101927 - 101927
Published: Jan. 25, 2025
Language: Английский
Pharmacogenomics-Based Detection of Variants Involved in Pain, Anti-inflammatory and Immunomodulating Agents Pathways by Whole Exome Sequencing and Deep
PubMed,
Journal Year:
2025,
Volume and Issue:
50(2), P. 98 - 111
Published: Feb. 1, 2025
Next-Generation
Sequencing
(NGS)
methods
specifically
Whole-Exome
(WES)
have
demonstrated
promising
findings
with
a
high
accuracy
of
91%-99%
in
Pharmacogenomics
(PGx).
A
PGx-based
panel
can
be
utilized
to
minimize
adverse
drug
reactions
(ADRs)
and
maximize
the
treatment
efficacy.
Remarkably,
Cancer
Pain
Management
(CPM)
is
cutting-edge
concept
modern
medicine.
Thus,
this
study
aimed
investigate
WES
results
by
containing
genes
involved
Pain,
Anti-inflammatory,
Immunomodulating
agents
(PAIma)
signaling
pathways.
total
200
unrelated
Iranians
(100
western
100
northern)
were
included.
analyzed
through
PAIma
panel.
After
DNA
extraction,
samples
genotyped
Multiplex-Amplification-Refractory
Mutation
System
(ARMS)
PCR.
primary
silico
investigation
performed
on
128
candidate
Protein-Protein
Interactions
(PPIs)
Gene-miRNA
(GMIs)
via
STRING
database,
miRTargetLink2,
respectively.
Additionally,
Enrichment
Analysis
(EA)
was
applied
find
unknown
interplays
among
these
three
major
pathways
Enrichr.
55,590
annotations
21
curated
filtered,
900
variants
found,
refined.
Finally,
54
(48
non-synonymous
single
nucleotide
(nsSNVs),
2
stop-gained,
1
frameshift,
3
splicing)
remained.
Conclusively,
six
potentially
actionable
including
rs1695
(GSTP1),
rs628031
(SLC22A1),
rs17863778
(UGT1A7),
rs16947
(CYP2D6),
rs2257401
(CYP3A7),
rs2515641
(CYP2E1)
had
most
deviations
Iranians,
compared
reference
genome,
which
should
for
prescribing.
PPIs,
GMIs,
EA
revealed
potential
risks
carcinogenesis
cancer
phenotypes
resulting
from
genes.
Language: Английский
Genetic and Regulatory Mechanisms of Comorbidity of Anxiety, Depression and ADHD: A GWAS Meta-Meta-Analysis Through the Lens of a System Biological and Pharmacogenomic Perspective in 18.5 M Subjects
Journal of Personalized Medicine,
Journal Year:
2025,
Volume and Issue:
15(3), P. 103 - 103
Published: March 5, 2025
Background:
In
the
United
States,
approximately
1
in
5
children
experience
comorbidities
with
mental
illness,
including
depression
and
anxiety,
which
lead
to
poor
general
health
outcomes.
Adolescents
substance
use
disorders
exhibit
high
rates
of
co-occurring
over
60%
meeting
diagnostic
criteria
for
another
psychiatric
condition
community-based
treatment
programs.
Comorbidities
are
influenced
by
both
genetic
(DNA
antecedents)
environmental
(epigenetic)
factors.
Given
significant
impact
on
individuals'
lives,
this
study
aims
uncover
common
mechanisms
through
a
Genome-Wide
Association
Study
(GWAS)
meta-meta-analysis.
Methods:
GWAS
datasets
were
obtained
each
comorbid
phenotype,
followed
meta-meta-analysis
using
significance
threshold
p
<
5E-8
validate
rationale
behind
combining
all
phenotypes.
The
combined
refined
dataset
was
subjected
bioinformatic
analyses,
Protein-Protein
Interactions
Systems
Biology.
Pharmacogenomics
(PGx)
annotations
potential
genes
at
least
one
PGx
tested,
identified
Genetic
Addiction
Risk
Severity
(GARS)
test,
included
10
eleven
Single
Nucleotide
Polymorphisms
(SNPs).
STRING-MODEL
employed
discover
novel
networks
Protein-Drug
interactions.
Results:
Autism
Spectrum
Disorder
(ASD)
as
top
manifestation
derived
from
known
interaction
depression,
attention
deficit
hyperactivity
disorder
(ADHD).
analysis
revealed
network
associated
these
comorbidities.
findings
suggest
that
interactions
linked
need
induce
"dopamine
homeostasis"
therapeutic
outcome.
Conclusions:
This
provides
reliable
epigenetic
map
could
assist
healthcare
professionals
care
patients
presenting
multiple
manifestations,
ADHD.
results
highlight
importance
targeting
dopamine
homeostasis
managing
ASD
These
insights
may
guide
future
pharmacogenomic
interventions
improve
clinical
outcomes
affected
individuals.
Language: Английский
Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital
Current Oncology,
Journal Year:
2024,
Volume and Issue:
31(3), P. 1335 - 1347
Published: March 5, 2024
Background:
Our
aim
was
to
examine
the
frequency
and
prescription
pattern
of
breakthrough
(BTO)
scheduled
(SCH)
opioids
their
ratio
(BTO/SCH
ratio)
use,
prior
after
referral
an
inpatient
supportive
care
consult
(SCC)
for
cancer
pain
management
(CPM).
Methods
Materials:
Patients
admitted
at
MD
Anderson
Cancer
Center
referred
a
SCC
were
retrospectively
reviewed.
patients
receiving
SCH
BTO
≥24
h
eligible
inclusion.
Patient
demographics
clinical
characteristics,
including
type
route
opioids,
daily
opioid
doses
(MEDDs)
BTO,
BTO/SCH
ratios
reviewed
in
seen
(pre-SCC)
during
SCC.
A
normal
defined
as
0.5–0.2.
Results:
total
665/728
(91%)
evaluable.
Median
scores
(p
<
0.001),
MEDDs
0.0001),
0.0001)
higher,
but
median
number
fewer
(2
vs.
4,
p
among
compared
pre-SCC.
over
recommended
(>0.2)
37.5%
patients.
The
pre-SCC
groups
0.10
(0.04,
0.21)
0.17
(0.10,
0.30),
respectively,
0.001.
Hydromorphone
Morphine
most
common
prescribed,
respectively.
early
group
had
higher
MEDDs.
Conclusions:
are
frequently
prescribed
than
dose.
Daily
scores,
MEDDs,
group,
doses/day
lower.
Language: Английский
DREZotomy in the era of minimally invasive interventions for cancer-related pain management
Annals of Medicine and Surgery,
Journal Year:
2024,
Volume and Issue:
86(8), P. 4327 - 4332
Published: June 15, 2024
Language: Английский
Integrating computational biology and multiomics data for precision medicine in personalized cancer treatment
Chandan Shivamallu,
No information about this author
Chattu Bhargavi,
No information about this author
S Bhavana
No information about this author
et al.
Elsevier eBooks,
Journal Year:
2024,
Volume and Issue:
unknown, P. 249 - 277
Published: Nov. 29, 2024
Language: Английский
A Review of the Impact of Touch Therapy on Cancer Treatment
Clinical Cancer Investigation Journal,
Journal Year:
2024,
Volume and Issue:
13(2), P. 1 - 5
Published: Jan. 1, 2024
Pain
is
one
of
the
common
and
painful
symptoms
in
cancer
patients.
affects
life
these
patients
sometimes
its
effect
more
than
itself.
Several
studies
have
investigated
using
various
non-pharmacological
interventions,
including
touch
therapy,
on
reducing
pain
patients,
which
yielded
different
results.
The
purpose
this
study
was
to
investigate
therapy
relief
pain.
Also,
study,
side
Language: Английский